Pharmaceutical - UK, Oncology

Filter

Current filters:

UKOncology

Popular Filters

1 to 25 of 94 results

England's cancer outcomes worse than rest of Europe: National Audit Office report

England's cancer outcomes worse than rest of Europe: National Audit Office report

16-01-2015

The UK’s National Audit Office has published a report, Progress in improving cancer services and outcomes…

Markets & MarketingOncologyPharmaceuticalPoliticsPricingResearchUK

Boehringer opts to take up rights to Oxford BioThera’s oncology target

Boehringer opts to take up rights to Oxford BioThera’s oncology target

14-01-2015

Privately-held, UK-based Oxford BioTherapeutics says that German family-owned pharma major Boehringer…

Boehringer IngelheimLicensingOncologyOxford BioTherapeuticsPharmaceuticalUK

NHS England raises budget for Cancer Drugs Fund but axes some products

NHS England raises budget for Cancer Drugs Fund but axes some products

13-01-2015

As has been widely expected and already much criticized, England’s over-stretched Cancer Drugs Fund…

FinancialHealthcareOncologyPharmaceuticalUK

GW and Otsuka report Sativex failed to meet primary endpoint in cancer pain

GW and Otsuka report Sativex failed to meet primary endpoint in cancer pain

09-01-2015

UK-based GW Pharmaceuticals and Japanese drugmaker Otsuka have reported that Sativex (nabiximols) did…

AnalgesiaGW PharmaceuticalsOncologyOtsuka PharmaceuticalPharmaceuticalResearchSativexUKUSA

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

08-01-2015

England’s Cancer Drugs Fund is overspent and 42 drugs are being reassessed as price caps are brought…

AvastinEisaiHalavenHealthcareJevtanaKadcylaOncologyPharmaceuticalPricingRocheSanofiUKZaltrap

UK’s NICE says cost of Celgene’s Abraxane is not justified by its limited benefit

UK’s NICE says cost of Celgene’s Abraxane is not justified by its limited benefit

30-12-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today published…

AbraxaneCelgene CorpOncologyPharmaceuticalRegulationUK

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

16-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

InlytaOncologyPfizerPharmaceuticalPricingRegulationUK

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

15-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) have recommended…

BayerOncologyPharmaceuticalPricingRegulationUKXofigo

FDA accepts NDA filing from AstraZeneca for Iressa

FDA accepts NDA filing from AstraZeneca for Iressa

02-12-2014

The US Food and Drug Administration has accepted for filing the New Drug Application from Iressa (gefitinib)…

AstraZenecaIressaOncologyPharmaceuticalRegulationUK

NICE reverses October decision and approves Roche's Gazyvaro

NICE reverses October decision and approves Roche's Gazyvaro

02-12-2014

The UK’s National Institute for Health and Care Excellence (NICE) has reversed its decision on Gazyvaro…

GazyvaroOncologyPharmaceuticalRegulationRocheUK

AstraZeneca signs drug discovery collaboration with Cancer Research UK

AstraZeneca signs drug discovery collaboration with Cancer Research UK

28-11-2014

UK pharma major AstraZeneca and charity Cancer Research UK have signed a memorandum of understanding…

AstraZenecaOncologyPharmaceuticalResearchUK

MHRA showcases benefit of its industry collaboration with AstraZeneca's Macclesfield plant

MHRA showcases benefit of its industry collaboration with AstraZeneca's Macclesfield plant

27-11-2014

The UK's Medicines and Healthcare products Regulatory Agency has published a case study outlining the…

AstraZenecaOncologyPharmaceuticalProductionUK

NICE updated guidance backs Novartis’ Glivec for GIST

26-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued final…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Oncology specialists say UK's capacity crisis is impacting patient care

Oncology specialists say UK's capacity crisis is impacting patient care

21-11-2014

A survey carried out by Swiss drug major Roche has shown that frontline staff believe patient care is…

Markets & MarketingOncologyPharmaceuticalResearchRocheUK

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

ABPI speaks out against changes to UK Cancer Drugs Fund medicines list

ABPI speaks out against changes to UK Cancer Drugs Fund medicines list

14-11-2014

The Association of the British Pharmaceutical Industry has spoken out against imminent changes to how…

NHSOncologyPharmaceuticalRegulationUK

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

13-11-2014

The UK’s National Health Service has updated its procedure for evaluating drugs in the Cancer Drugs…

AvastinKadcylaOncologyPharmaceuticalRegulationSprycelUK

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

10-11-2014

The Scottish Medicines Consortium has approved two new treatments today, one for skin cancer and one…

Bristol-Myers SquibbDaklinzaNephrology and HepatologyOncologyPharmaceuticalRegulationUKYervoy

Scottish backing for Novartis’ Afinitor for kidney cancer patients

Scottish backing for Novartis’ Afinitor for kidney cancer patients

10-11-2014

The Scottish Medicines Consortium has issued a positive recommendation for Swiss pharma major Novartis’…

AfinitorClinical pharmacologyHealthHealth Medical PharmaNHSNovartisOncologyPharmaceuticalPricingRegulationUK

UK's NICE recommends GSK's Arzerra for untreated chronic lymphocytic leukemia

UK's NICE recommends GSK's Arzerra for untreated chronic lymphocytic leukemia

04-11-2014

The UK’s National Institute for Health and Care Excellence has issued new preliminary draft guidance…

ArzerraGSKOfatumumab InjectionOncologyPharmaceuticalRegulationUK

Elderly UK patients with rare blood cancer receive substandard care

Elderly UK patients with rare blood cancer receive substandard care

28-10-2014

Elderly people in the UK with Myelodysplastic Syndromes (MDS), a rare form of blood cancer, are not being…

Celgene Corp.HealthcareOncologyPharmaceuticalResearchUK

The cancer drug discovery system is broken, global summit hears

The cancer drug discovery system is broken, global summit hears

24-10-2014

Here's our take on the week's top stories.

CancerOncologyPharmaceuticalResearchUK

NICE recommends another new skin cancer drug, GSK’s Tafinlar

22-10-2014

The UK National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTafinlarUK

1 to 25 of 94 results

Back to top